Literature DB >> 22939387

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

Pamela J Maxwell1, Jonathan Coulter, Steven M Walker, Melanie McKechnie, Jessica Neisen, Nuala McCabe, Richard D Kennedy, Manuel Salto-Tellez, Chris Albanese, David J J Waugh.   

Abstract

BACKGROUND: Inflammation and genetic instability are enabling characteristics of prostate carcinoma (PCa). Inactivation of the tumour suppressor gene phosphatase and tensin homolog (PTEN) is prevalent in early PCa. The relationship of PTEN deficiency to inflammatory signalling remains to be characterised.
OBJECTIVE: To determine how loss of PTEN functionality modulates expression and efficacy of clinically relevant, proinflammatory chemokines in PCa. DESIGN, SETTING, AND PARTICIPANTS: Experiments were performed in established cell-based PCa models, supported by pathologic analysis of chemokine expression in prostate tissue harvested from PTEN heterozygous (Pten(+/-)) mice harbouring inactivation of one PTEN allele.
INTERVENTIONS: Small interfering RNA (siRNA)- or small hairpin RNA (shRNA)-directed strategies were used to repress PTEN expression and resultant interleukin-8 (CXCL8) signalling, determined under normal and hypoxic culture conditions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Changes in chemokine expression in PCa cells and tissue were analysed by real-time polymerase chain reaction (PCR), immunoblotting, enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry; effects of chemokine signalling on cell function were assessed by cell cycle analysis, apoptosis, and survival assays. RESULTS AND LIMITATIONS: Transient (siRNA) or prolonged (shRNA) PTEN repression increased expression of CXCL8 and its receptors, chemokine (C-X-C motif) receptor (CXCR) 1 and CXCR2, in PCa cells. Hypoxia-induced increases in CXCL8, CXCR1, and CXCR2 expression were greater in magnitude and duration in PTEN-depleted cells. Autocrine CXCL8 signalling was more efficacious in PTEN-depleted cells, inducing hypoxia-inducible factor-1 (HIF-1) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription and regulating genes involved in survival and angiogenesis. Increased expression of the orthologous chemokine KC was observed in regions displaying atypical cytologic features in Pten(+/-) murine prostate tissue relative to normal epithelium in wild-type PTEN (Pten(WT)) glands. Attenuation of CXCL8 signalling decreased viability of PCa cells harbouring partial or complete PTEN loss through promotion of G1 cell cycle arrest and apoptosis. The current absence of clinical validation is a limitation of the study.
CONCLUSIONS: PTEN loss induces a selective upregulation of CXCL8 signalling that sustains the growth and survival of PTEN-deficient prostate epithelium.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; CXCL8; CXCR2; Hypoxia; Inflammation; PTEN; Prostate cancer

Mesh:

Substances:

Year:  2012        PMID: 22939387      PMCID: PMC4185293          DOI: 10.1016/j.eururo.2012.08.032

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  30 in total

1.  Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.

Authors:  Catherine Murphy; Maryalice McGurk; Johanna Pettigrew; Alfredo Santinelli; Roberta Mazzucchelli; Patrick G Johnston; Rodolfo Montironi; David J J Waugh
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

2.  Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts.

Authors:  Satoshi Anai; Steve Goodison; Kathleen Shiverick; Kenneth Iczkowski; Motoyoshi Tanaka; Charles J Rosser
Journal:  Hum Gene Ther       Date:  2006-10       Impact factor: 5.695

Review 3.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

4.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation.

Authors:  Robert D Loberg; LaShon L Day; Jason Harwood; Chi Ying; Lauren N St John; Ryan Giles; Chris K Neeley; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

5.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

6.  The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy.

Authors:  L A Begley; S Kasina; J MacDonald; J A Macoska
Journal:  Cytokine       Date:  2008-06-24       Impact factor: 3.861

7.  Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.

Authors:  Catherine Wilson; Timothy Wilson; Patrick G Johnston; Daniel B Longley; David J J Waugh
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

8.  Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.

Authors:  Núria de la Iglesia; Genevieve Konopka; Kah-Leong Lim; Catherine L Nutt; Jacqueline F Bromberg; David A Frank; Paul S Mischel; David N Louis; Azad Bonni
Journal:  J Neurosci       Date:  2008-06-04       Impact factor: 6.167

9.  Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.

Authors:  Angela Seaton; Paula Scullin; Pamela J Maxwell; Catherine Wilson; Johanna Pettigrew; Rebecca Gallagher; Joe M O'Sullivan; Patrick G Johnston; David J J Waugh
Journal:  Carcinogenesis       Date:  2008-05-16       Impact factor: 4.944

10.  HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.

Authors:  P J Maxwell; R Gallagher; A Seaton; C Wilson; P Scullin; J Pettigrew; I J Stratford; K J Williams; P G Johnston; D J J Waugh
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

View more
  39 in total

Review 1.  Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.

Authors:  Ian G Mills
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

3.  Development of animal models underlining mechanistic connections between prostate inflammation and cancer.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2013-02-10

4.  Prognostic significance of neutrophil to lymphocyte ratio in patients with gallbladder carcinoma.

Authors:  Lingqiang Zhang; Ruitao Wang; Wei Chen; Xinsen Xu; Shunbing Dong; Haining Fan; Chang Liu
Journal:  HPB (Oxford)       Date:  2016-05-06       Impact factor: 3.647

Review 5.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

6.  Epithelial-mesenchymal transition in cancer: Role of the IL-8/IL-8R axis.

Authors:  Zhiwei Zhao; Shichao Wang; Yingbo Lin; Yali Miao; Ye Zeng; Yongmei Nie; Peng Guo; Guangyao Jiang; Jiang Wu
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

7.  PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer.

Authors:  Chao Wang; Yaping Feng; Chengyue Zhang; David Cheng; Renyi Wu; Yuqing Yang; Davit Sargsyan; Dibyendu Kumar; Ah-Ng Kong
Journal:  FASEB J       Date:  2019-11-29       Impact factor: 5.191

8.  Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma.

Authors:  Chris W D Armstrong; Jonathan A Coulter; Chee Wee Ong; Pamela J Maxwell; Steven Walker; Karl T Butterworth; Oksana Lyubomska; Silvia Berlingeri; Rebecca Gallagher; Joe M O'Sullivan; Suneil Jain; Ian G Mills; Kevin M Prise; Robert G Bristow; Melissa J LaBonte; David J J Waugh
Journal:  NAR Cancer       Date:  2020-07-03

Review 9.  Prostate carcinogenesis: inflammatory storms.

Authors:  Johann S de Bono; Christina Guo; Bora Gurel; Angelo M De Marzo; Karen S Sfanos; Ram S Mani; Jesús Gil; Charles G Drake; Andrea Alimonti
Journal:  Nat Rev Cancer       Date:  2020-06-16       Impact factor: 60.716

10.  NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis.

Authors:  Dinesh Thapa; Peng Meng; Roble G Bedolla; Robert L Reddick; Addanki P Kumar; Rita Ghosh
Journal:  Cancer Res       Date:  2014-08-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.